Mana.bio

A First in Rare Disease Genetics: Emma’s Story and the Untapped Power of ‘Junk DNA’ Emma Broadbent's groundbreaking diagnosis as the first patient with a disorder caused by CHASERR lncRNA deletion showcases the profound potential of exploring non-coding DNA. Her story underscores the importance of these "genomic dark regions" in rare disease diagnosis. Join us at PMWC 2025 in the CGT in Rare Disease Track (Feb. 5-7) to delve into the latest advancements in rare disease research: ~Keynote: Bioorthogonal Chemistry, from Basic Science to Clinical Translation Carolyn Bertozzi, Stanford ~Keynote: The Promise of Genetic Medicines Unless You're Too Poor or Too Rare- James M. Wilson, GEMMA Biotherapeutics ~Addressing Ethical and Financial Barriers in Gene Therapy Chair: Tim Hunt, Alliance for Regenerative Medicine ~Next-Generation Delivery Systems for Gene Therapies Chair: Morten Sogaard, Astellas Gene Therapies Panelists: Mathieu Nonnenmacher (Voyager Therapeutics, Inc.), Kevin Friedman (Kelonia Therapeutics), Kunwoo Lee (GenEdit), Haig Aghajanian (Capstan Therapeutics) ~Beyond the Genome: Harnessing Epigenetics in Rare Disease Treatment Chair: Charles Gersbach, Duke Panelists: Prashant Mali, (UCSD), Nadav Ahituv (UCSF), Blythe Sather (Tune Therapeutics), Fyodor Urnov (Berkeley University) ~Navigating the Regulatory Landscape for Gene and Cell Therapies Chair: Yael Weiss, Mahzi Therapeutics Panelists: Courtney Silverthorn (BGTC), Peter Marks (FDA), Benjamin Dewees (Kyverna Therapeutics) ~AI-driven Improvements in Gene and Cell Therapy Chair: Morten Sogaard, Astellas Panelists: Francois Vigneault (Shape Therapeutics Inc.), John Androsavich (Ginkgo Bioworks, Inc.), Yogev Debbi (Mana.bio) See program: https://lnkd.in/gPtkWZbQ Emma's story by BioQuick News- https://shorturl.at/LEMcc PMWC - Precision Medicine World Conference, Mike O'Neill #PMWC2025 #RareDiseases #PrecisionMedicine #Genomics #HealthcareInnovation #GeneticResearch #NonCodingDNA #RareDiseaseAwareness #GenomicInnovation #GeneTherapy #PersonalizedMedicine

Our CEO Yogev Debbi is speaking next week at the 14th annual #PODD - Partnership Opportunities In Drug Delivery Conference in Boston. Stop by to see our company presentation on Tuesday, October 29th during the Soapbox Presentations from 11:55-12:40 pm ET.

Our dear Scientific Co-founder Kira Radinsky was interviewed to Crafted. and shared her opinion on AI, how we use it at Mana and the future potential of AI in life science. Excited to have such amazing team members with us, on our mission to unlock RNA delivery with our programmable AI platform. Links to listen below

News Update: Our team has signed a collaborative research agreement with Sheba Medical Center, Tel Hashomer. Through this study we plan to utilize our programmable AI platform to enhance personalized medicine by using RNA delivery to reprogram T-cells in the fight against challenging diseases such as cancer and autoimmune disorders. We are excited to be working with Sheba Medical Center on such a novel study to push the boundaries of RNA delivery. Our AI based programmable platform enables the discovery of efficient, safe, more precise delivery formulations - providing us the opportunity to unlock the full potential of RNA therapies across a wide range of disease areas. https://lnkd.in/dHueK-yU #RNA #LNP #AI

We’ve been recognized by TheMarker as one of the Top 20 promising start-ups in Israel alongside PhaseV, Protai, caVos Biotherapeutics, and more. This is a testament to the resilience of our community - so many exciting ideas becoming a reality. You can read the full piece here: https://lnkd.in/dmQpZQQH

We're proud to announce that Mana has been accepted into the #NVIDIAInception program. We are honored to be part of a group of startups driving changes in #AI across industries and around the world. This program will provide us with several opportunities, including access to NVIDIA's latest technological resources and the chance to connect with peers who are working through similar challenges. This is yet another exciting milestone for us as we continue to grow and work to find improved RNA delivery options.

Proud of our Scientific co-founder Prof. Avi Schroeder for being appointed to be the President of the Controlled Release Society! We wish Avi and the community much impact and success ahead.

Our CEO Yogev Debbi recently published his thoughts on the importance of speaking the language of AI in Pharma and why the future of human health depends on it. Dig into why the industry needs to do more engineering and less gambling when it comes to drug development and how to best re-frame the way lab work is measured in order to best embrace AI. See the full piece below #pharma #AI #lab #data

We are excited to sponsor a Workshop at the Controlled Release Society conference this morning on The Application of AI to Drug Delivery. Co-sponsored with METiS Therapeutics and organized by Daniel Heller and Avi Schroeder, in the beautiful Bologna, Italy. Come and listen to so many terrific experts in this area. #AI #drugdelivery #LNP #data

💊 𝗡𝗮𝗻𝗼𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆-𝗯𝗮𝘀𝗲𝗱 𝗗𝗿𝘂𝗴 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺𝘀: 𝟱 𝗦𝘁𝗮𝗿𝘁𝘂𝗽𝘀 𝘁𝗼 𝗪𝗮𝘁𝗰𝗵! 👀 🔵 The growing use of nanotechnology in drug delivery is transforming healthcare by allowing for targeted, efficient, and controlled release of medications! 🔵 These young companies are great examples of startups leading the way in this transformation, developing state-of-the-art technologies that improve the precision and effectiveness of treatments! 🔵 From targeted cancer treatments to advanced gene therapies, these startups are laying the groundwork for a new era in medicine! 🔵 Take a look through the startups in our list: 💠 Aera Therapeutics 💠 Orion Therapeutics, Inc. 💠 NanoPhoria 💠 NanoVation Therapeutics™ 💠 Mana.bio ---------------------------------------------- What startups can you add to the list? Source: VentureRadar #startup #drugdelivery #lipidnanoparticle #LNP #liposome #biotechnology #biopharmaindustry #nanotechnology